High Point Advisor Group LLC Nymox Pharmaceutical Corp Transaction History

High Point Advisor Group LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 10, 2021	SELL	$1.84 - $2.83 $62,560 - $96,220	-34,000 Closed	0 $0
Q1 2020 May 01, 2020	BUY	$1.69 - $3.88 $57,294 - $131,539	33,902 Added 34593.88%	34,000 $98,000
Q1 2020 Apr 27, 2020	SELL	$1.69 - $3.88 $57,294 - $131,539	-33,902 Reduced 99.71%	98 $34 Million
Q4 2019 Feb 13, 2020	BUY	$1.73 - $2.42 $58,820 - $82,280	34,000 New	34,000 $102,000

150K

Ticker NYMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 91,265,000
Market Cap $42.9M
Description
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperpl...

Get notified when there are updates to the investment portfolio of High Point Advisor Group LLC, based on Form 13F filings with the SEC.

Stay updated on High Point Advisor Group LLC with notifications on news.